Pfizer (NYSE:PFE) just recently dropped a multibillion-dollar bombshell on the market, which appears to have shrugged it off. Pfizer was up just slightly in Monday afternoon’s trading, despite the fact that Pfizer now looks for mRNA vaccine revenue to clear between $10 billion and $15 billion by 2030. Mainly, Pfizer’s mRNA vaccine arsenal focuses on COVID-19. However, there’s more to the story than that.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The company also has vaccines in the works for shingles as well as the flu. Perhaps best of all for those who want such vaccines, the company recently landed a “fast-track designation” for a planned combination treatment. The combination treatment will address both COVID-19 and the flu at the same time.
The $10 to $15 billion expected is an aggregate figure. However, the components making up that aggregate are impressive enough. The proceeds from the respiratory syncytial virus (RSV) candidate alone are expected to clear over $2 billion by itself just between 2023 and 2027.
This should be good news for Pfizer and for its investors. Pfizer has been on a decline for much of the last year. It dropped from a high of $59.77 to a low of $41.09. Many investors wondered what Pfizer would do to replace its revenue stream from COVID-19 vaccines. Especially after everyone who wanted that shot had it. However, it’s clear that Pfizer has new acts waiting in the wings that should give the company new life.
